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Abstract
Background: Disruptive mutation in the CHD8 gene is one of the top genetic risk factors in autism spectrum
disorders (ASDs). Previous analyses of genome-wide CHD8 occupancy and reduced expression of CHD8 by shRNA
knockdown in committed neural cells showed that CHD8 regulates multiple cell processes critical for neural
functions, and its targets are enriched with ASD-associated genes.
Methods: To further understand the molecular links between CHD8 functions and ASD, we have applied the
CRISPR/Cas9 technology to knockout one copy of CHD8 in induced pluripotent stem cells (iPSCs) to better mimic
the loss-of-function status that would exist in the developing human embryo prior to neuronal differentiation.
We then carried out transcriptomic and bioinformatic analyses of neural progenitors and neurons derived from
the CHD8 mutant iPSCs.
Results: Transcriptome profiling revealed that CHD8 hemizygosity (CHD8+/−) affected the expression of several
thousands of genes in neural progenitors and early differentiating neurons. The differentially expressed genes
were enriched for functions of neural development, β-catenin/Wnt signaling, extracellular matrix, and skeletal
system development. They also exhibited significant overlap with genes previously associated with autism and
schizophrenia, as well as the downstream transcriptional targets of multiple genes implicated in autism. Providing
important insight into how CHD8 mutations might give rise to macrocephaly, we found that seven of the twelve
genes associated with human brain volume or head size by genome-wide association studies (e.g., HGMA2) were
dysregulated in CHD8+/− neural progenitors or neurons.
Conclusions: We have established a renewable source of CHD8+/− iPSC lines that would be valuable for
investigating the molecular and cellular functions of CHD8. Transcriptomic profiling showed that CHD8 regulates
multiple genes implicated in ASD pathogenesis and genes associated with brain volume.
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Background
ASDs are a class of neurodevelopmental disorders char-
acterized by persistent deficits in social communication/
interaction and restricted, repetitive patterns of behav-
iors, interests, or activities (DSM-5) [1]. The genetic risk
factors for ASD are heterogeneous, and up to 1 thousand
genes are estimated to be involved [2]. Recent whole ex-
ome and genome-sequencing projects, focused on the
identification of rare de novo mutation in the probands
of ASD family “trios” or “quads”, have discovered hun-
dreds of genes with functionally disruptive mutations
[3–12], some of which also map to ASD-associated de
novo copy number variations (CNVs) [13]. Many of the
implicated genes encode proteins involved in synapse
formation, transcriptional regulation, and chromatin re-
modeling [10, 14], indicating a likely convergence of
functional pathways, despite genetic heterogeneity.
Chromodomain helicase DNA binding protein 8 (CHD8)
emerged as a top ASD-candidate gene from multiple
exome-sequencing studies [6, 8], which altogether have an-
alyzed thousands of ASD probands and in some cases their
families too [15, 16]. More importantly, disrupting chd8 in
zebrafish development has recapitulated multiple features
of ASD, including macrocephaly observed in some ASD
cases carrying CHD8 mutations [15, 16]. In addition,
macrocephaly is often found in ASD caused by disruption
of other candidate genes [17].
CHD8 is a ubiquitously expressed member of the CHD
family of ATP-dependent chromatin-remodeling factors
that play important roles in chromatin dynamics, transcrip-
tion, and cell survival [18]. Previous studies [19–21] have
shown that the CHD8 protein interacts with β-catenin
and negatively regulates Wnt signaling, while both β-
catenin and Wnt signaling play critical roles in normal
brain development and neuropsychiatric disorders [22],
including ASD [14]. CHD8 also functionally interacts
with p53 [23] and recruits MLL histone methyltransfer-
ase complexes to regulate cell cycle genes [24].
To elucidate the roles of CHD8 in neurodevelopment
and address the contribution of its disruption to ASD
pathogenesis, three groups have recently reported genome-
wide CHD8 binding sites and transcriptomic changes upon
shRNA-mediated knockdown of CHD8 expression in
neural progenitor cells (NPCs) [25], neural stem cells
(NSCs) [26], and SK-N-SH neuroblastoma cells [27]. The
results showed that CHD8 binds to thousands of genes,
largely biased to promoters, in NPCs, NSCs, and develop-
ing mammalian brains. Reduced expression of CHD8
resulted in the potential disruption of gene networks in-
volved in neurodevelopment, which contained many ASD-
risk genes [15, 25–27]. The transcriptional targets of
CHD8 have also been studied in non-neural systems, as it
is also involved in cell cycle regulation, Wnt signaling, and
several forms of cancers [19, 21, 24, 28, 29].
As ASD is a developmental disorder with symptoms
emerging in early childhood and the CHD8 causal muta-
tions in patients are germline, it is important to establish
cell models that can mimic the persistent loss of CHD8
function in the developing embryos prior to and during
neuronal differentiation and brain development. There-
fore, we applied CRISPR/Cas9 technology [30] to gener-
ate CHD8+/− iPSCs by knocking out one copy of the
gene in an iPSC line derived from a healthy male sub-
ject. We then differentiated both the wild-type (WT)
and the CHD8+/− iPSCs to NPCs and subsequently neu-
rons and performed comparative transcriptomic analysis
(RNA-seq). Our approach has several advantages: pre-
cisely targeted changes at the DNA level, persistent re-
duction of CHD8 expression, no introduction of extra
genetic materials (e.g., virus vector) to the cells, and
greater flexibility in the types of differentiated cells that
can be generated.
We found that heterozygous CHD8 knockout (KO)
disrupted the expression of many genes involved in
extracellular matrix formation, neuronal differentiation,
and skeletal system development. Interestingly, CHD8-
regulated genes were enriched with ASD-risk genes,
schizophrenia-risk genes, and genes implicated in regu-
lating head size or brain volume. Furthermore, we found
that CHD8-regulated genes significantly overlapped with
the downstream targets of several critical genes (TCF4,
EHMT1, SATB2, and NRXN1) that have been associated
with ASD or other neuropsychiatric disorders. Taken to-
gether, our results not only shed light on the molecular
roles of CHD8 in neurodevelopment, but also provide
evidence of potential convergence of cellular pathways
that could be disrupted by mutations of distinct ASD-
risk genes.
Methods
Development of iPSCs from skin fibroblasts
We have been developing iPSCs from controls and pa-
tients with 22q11.2 deletion and diagnosis of a psychotic
disorder [31]. The study and consent forms were ap-
proved by the Institutional Review Board of Albert Ein-
stein College of Medicine . Consent was obtained by a
skilled member of the research team who had received
prior human subject training. One of the healthy male
control (without 22q11.2 del too) was used in the
current study. Exome sequencing was performed on
DNA extracted from white blood cells of this subject to
detect coding variants prior to generating the CHD8
KO. We used GATK [32] for variant calling and ANNO-
VAR [33] for variant annotation.
The iPSC line used in this study was generated from
fibroblasts obtained from a skin biopsy performed by a
board-certified dermatologist. The procedures for grow-
ing fibroblasts and iPSC reprogramming are detailed in
Wang et al. Molecular Autism  (2015) 6:55 Page 2 of 18
Additional file 1. Pluripotency was confirmed by im-
munocytochemistry using antibodies (Ab) against Tra-1-
60, Tra-1-81, SSEA3, and SSEA4, which are expressed in
pluripotent stem cells. In addition, the capacity to differ-
entiate into all three germ layers was established by in
vitro assays, as previously described (see Additional file
1 for details) [34, 35].
Design of the CHD8 single guide RNA sequences
Single guide RNA (sgRNA) sequences targeting the re-
gion adjacent to the Ser62 codon of CHD8 were picked
using the online CRISPR design tool [36] from the
Zhang lab at the Broad Institute, and the two selected
sgRNAs were predicted to have very low probability off-
target sites. The sgRNA sequences were then cloned into
the pSpCas9 (BB)-2A-Puro (PX459) vector (a gift from
Dr. Feng Zhang, Addgene plasmid # 48139) [30].
CRISPR/Cas9-mediated CHD8 knockout
Human iPSCs were cultured and fed daily in mTeSR1
(Stem Cell technologies) on Matrigel (BD)-coated
plates at 37 °C/5 % CO2/85 % in a humidified incuba-
tor. Cells were maintained in log phase growth, and dif-
ferentiated cells were manually removed. iPSCs were
exposed to 10-μM ROCK Inhibitor for ~4 h to improve
cell survival during nucleofection. After 4 h, growth
medium was aspirated, and the cells were rinsed with
DMEM/F12. iPSCs were dissociated into single cells
using accutase and harvested. Nucleofection was per-
formed using the Amaxa-4D Nucleofector Basic Proto-
col for Human Stem Cells (Lonza) according to the
manufacturer’s instructions. Briefly, 8 × 105 cells and
5 μg of the CRISPR/Cas9 plasmids with either sgRNA1
or sgRNA2 were nucleofected using the P3 Primary
Cell 4D-Nucleofector X Kit L with program CA-137.
Cells were resuspended in mTeSR1 + 10-μM ROCK In-
hibitor and placed in one well of a 6-well Matrigel-
coated plate. The following day, cells were fed with
fresh mTeSR1, and were subsequently fed with fresh
medium every day. On days 4–14, cells were exposed to
0.5 μg/ml puromycin for 6 h. Puromycin-resistant col-
onies were picked and expanded in mTeSR1 without
further puromycin treatment.
Characterizing CHD8 knockout lines
“TA” cloning was used to identify the knockout alleles. A
479-bp PCR amplicon flanking the CRSPR/Cas9-targeted
sites was generated using the primers 5’-CTGTAAGA-
CAGGTTGGGCTG-3’ and 5’-CTTGTTTCTTGCCTCT
ATACTTGA-3’. The PCR product was purified and li-
gated into pCR™2.1 using a TA Cloning Kit developed by
Life Technologies following the manufacturer’s proto-
col. Recombinant plasmids were introduced into com-
petent E. coli and selected in ampicillin. Plasmid DNA
was extracted and sequenced across the insert using
one of the PCR primers.
Western blotting confirmed that the CHD8+/− lines
expressed lower levels of CHD8 protein. Specifically, cell
lysates from NPCs differentiated from WT, and KO iPSCs
were separated by SDS PAGE, transferred to PVDF mem-
branes, and then blotted with anti-CHD8 antibody (Bethyl
Cat #A301-224A). Anti-actin antibody (BD Biosciences,
Cat # 612656) was used for loading control.
Neuronal differentiation
Neurons were generated from iPSC-derived NPCs as
described by Marchetto et al. with slight modifications
[34, 37]. A detailed description of the protocol can be
found in Additional file 1. Essentially, the protocol leads to
a mixed population of glutamatergic and GABAergic
neurons, from which RNA was extracted and sent for
sequencing.
RNA-seq analysis
We obtained 101-bp paired-end RNA-seq reads from Illu-
mina HiSeq 2500. RNA-seq reads were aligned to the
human genome (hg19) using Tophat (version 2.0.8) [38].
The number of RNA-seq fragments mapped to each gene
was determined for genes in the GENCODE database
(v18) [39]. Exonic/intronic/intergenic rates were calcu-
lated by CollectRnaSeqMetrics in Picard [40]. Cufflink
(version 2.2.1) [41] was used to generate the gene-
expression values as FPKMs (fragments per kilobase of
exon per million fragments mapped). We restricted our
analysis to 12,843 protein-coding genes with average
FPKM >1 across all four samples. DESeq2 [42] was used
to determine differentially expressed genes (DEGs) in
NPCs and neurons. The list of significantly DEGs was de-
fined at false discovery rate (FDR) < 0.05. DAVID [43, 44]
was used for Gene Ontology (GO) analysis with 12,843
expressed protein-coding genes as background. Ingenuity
pathway analysis (IPA) [45] was used for canonical path-
way analysis and disease association, with the ingenuity
knowledge base (genes only) as background. Toppgene
[46] was used for human phenotype ontology analysis,
and the whole genome was used as background. The
RNA-seq data have been deposited in the Gene Expres-
sion Omnibus (GEO; accession # GSE71594).
To find neurodevelopment genes specifically affected by
CHD8+/−, we added an interaction design in DESeq2 (op-
tion: ~celltype + genotype + celltype:genotype) to specific-
ally model the interactions between development status
(NPCs or neurons) and CHD8 status (WT or KO).
Validating targeted deletions and assessing off-targets
using RNA-seq reads
First, we examined if CHD8 was targeted and edited pre-
cisely according to our CRISPR sgRNA design. A 2-bp
Wang et al. Molecular Autism  (2015) 6:55 Page 3 of 18
deletion in chr14:21899785 (hg19) and a 10-bp deletion
in chr14:21899722 (hg19) were identified in a proportion
of RNA-seq reads that mapped to targeted regions of
the two CRISPR sgRNAs in CHD8+/− samples (KO1 and
KO2, respectively). This was confirmed by DNA sequen-
cing. The two short indels were not found in any of the
WT samples. We also called short indels (supported by
at least five RNA-seq reads) from RNA-seq reads by
samtools [47], but we did not detect any additional
indels that were present in CHD8+/− samples but not in
the WT controls.
Quantitative real-time PCR (qPCR)
qPCR was carried out on reverse transcribed PCR using
the 2−ΔΔCt method as previously described [48, 49]. A
detailed description and the primers used for this ana-
lysis can be found in Additional file 1.
Definition of CHD8-binding genes
ChIP-seq peaks of CHD8-binding sites in NPCs were
from Sugathan’s report [25]. Only peaks replicated by all
three antibodies were used. Genes with at least one peak
from 2 kb upstream of the transcription start sites to the
transcription terminus were defined as CHD8-binding
genes.
Interaction network analysis
DEGs in NPCs with CHD8-binding were imported into
the STRING database v10 [50] to construct protein-
protein interaction networks. We retained any inter-
action (i.e., edge) from experiments and databases that
had a median confidence ≥0.4.
For detecting converged networks of multiple ASD-
risk genes, we first collected DEG lists from our
CHD8+/− NPCs, TCF4 knockdown, EHMT1 knock-
down, MBD5 knockdown, and SATB2 knockdown, re-
spectively [51, 52], and then imported genes shared by
at least two lists into the STRING database to con-
struct gene networks. GO enrichment was calculated
by “Enrichment” function in STRING. Networks were
visualized using Cytoscape [53]. The same approach
was also applied to DEGs from CHD8 KO, ZNF804A
KD, and NRXN1 KD neurons.
Upstream regulator prediction
IPA was used to predict upstream regulators for 841
DEGs without CHD8 binding in NPCs. In this analysis,
the p value from IPA measures the significance in over-
lap between query genes and pre-defined sets of genes
that are regulated by a specific regulator, using the
Fisher test. At the end, we used p < 0.05 to select up-
stream regulators that (a) regulated at least five non
CHD8-bound DEGs and, themselves, were (b) in our
NPC DEG list.
ASD/schizophrenia-risk gene sets
The first ASD gene set was obtained from the SFARI
gene-scoring module [54], using genes scored as high
confidence, to minimal evidence and syndromic. The
second ASD gene set was from the AutismKB [55] core
dataset, which includes syndromic autism related genes
and non-syndromic-related genes, designated as high
confidence. High-confidence and probable ASD genes
in Willsey’s paper [56] were used as the third set
(“Willsey_ASD”). Genes predicted from whole exome-
sequencing and co-expression network [57] were used
as another set (“Liu_ASD”). The other two lists were
derived from massive whole exome sequencing: one
(“Iossifov_ASD”) focused on de novo mutations [11]
and the other (“DeRubeis_ASD”) combined de novo
and inherited mutations to develop a high-confidence
list (FDR < 0.1) [10]. Two schizophrenia gene lists were
from the SZgene database [58] and a recent GWAS re-
port [59].
Identification of common GO terms for DEG lists from
different CHD8 studies
DEGs were determined by the following criteria from
data in four previous studies. For the study by Cotney et
al. [26], we selected genes with logFC > 0.1 and log
counts per million (logCPM) between 2 and 10 to meet
the Poisson assumption, as described by the original
authors. However, we repeated differential expression
analysis with a less stringent FDR cutoff, using the
Benjamini-Hotchberg method instead of Bonferroni to
adjust p values for significance. For the study by
Sugathan et al. [25], we used ComBat in the sva package
[60] to adjust batch effects, followed by differential ex-
pression analysis with DESeq2 [42]. DEGs were selected
by p value < 0.05; 96 % of DEGs in Sugathan’s list were
in our reanalysis list. For Wilkinson et al’s study [27], we
used the DEG list provided by the authors.
Enriched GO terms for each of the five DEG lists were
first determined by ClueGO [61] (p value < 0.05). Subse-
quently, GO terms shared by ≥3 DEG lists were consid-
ered as common and used for subsequent analysis of
function overlap between the five CHD8+/− and knock-
down studies. The relationships among the selected GO
terms were based on their shared genes, which was mea-
sured using kappa statistics [62]. Two GO terms were
connected by an edge if they had a kappa score >0.4.
ClueGO relies on term similarity to define functional
groups of multiple terms. In our analysis, we set initial
group size to 5 (default value, 2) and percentage for
group merge (default values, 50 %) to 80 % to obtain a
summary of less redundant functional clusters of com-
mon GO terms. Since a GO term can be included in
several functional groups, we assigned each term only
to the functional groups in which it had the most
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significant group p values, meaning that this term had
the most similar genetic component in this group. Sub-
sequently, terms of the same groups formed a closed
circle. In addition to edges connecting terms to show
their relationships, we also added edges between terms
and studies to reveal enrichment of specific GO terms
among individual DEG lists.
Statistics
To test if DEGs were significantly overlapped/enriched
with a specific gene set, 12,843 expressed genes in our
samples were used as background (of all genes) for the
Fisher exact test. Statistics tests were conducted in R
[63] and multiple test correction was applied unless spe-
cified otherwise.
Results
Characterization of CHD8 knockout iPSC lines
Several functional disruptive mutations, including pre-
mature stop codons and frameshift mutations, have been
detected in CHD8 in ASD probands [15, 16]. We de-
signed two separate CRISPR sgRNA sequences to target
the N-terminal of CHD8 protein to generate truncated
mutations (Fig. 1a). iPSCs derived from a healthy male
subject were transduced with CRISPR/Cas9 vectors con-
taining each of the two target sequences. After screen-
ing, two clones, one with a 2-bp (KO1) and the other
with a 10-bp (KO2) heterozygous deletion were found;
the other allele was intact in both (Fig. 1b). Both gen-
omic DNA sequencing and Western blotting analysis




Fig. 1 Generation and characterization of CHD8+/− lines. a Design of CRISPR guide sgRNA sequences targeting the N-terminal end of CHD8.
The red marks Ser62 where premature stop codon mutations were uncovered from whole exome-sequencing analysis of ASD individuals [16].
b DNA-sequencing analysis of CHD8+/− iPSC clones. Knockout alleles were identified by cloning of PCR products and Sanger sequencing. c Western
blot analysis of CHD8+/− NPCs. CHD8-specific antibodies were used to detect CHD8 protein in NPC lysates. A clone with homozygous CHD8 knockout
(G2C2) was also analyzed, but this clone could not differentiate into neurons appropriately and thus was not included in our RNA-seq analysis.
d Validation of 2-bp (KO1, left) and 10-bp (KO2, right) deletion by RNA-seq reads. A screen shot of RNA-seq reads mapped to the CRISPR targeting
regions, with gap showing deletion
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for both clones. The CHD8+/− iPSC lines were used to
generate NPCs and early differentiating neurons for
RNA-seq analysis, together with samples prepared from
the parental WT clones, for a total of eight samples (two
biological replicates of WT and CHD8+/− at two neuro-
developmental stages).
Genes with altered expression in CHD8+/− are involved in
neurodevelopment
During RNA-seq analysis, we obtained on average ~28 mil-
lion read pairs per sample (Additional file 2: Table S1).
Examination of the RNA-seq reads mapped to the CHD8
exons confirmed the 2-bp and 10-bp deletion (Fig. 1d),
indicating that both the WT and KO CHD8 copies were
expressed in NPCs and neurons, with fewer reads from
the KO copy than the WT. Importantly, our indel analysis
of the RNA-seq reads detected no off-target sites at cod-
ing regions (see Methods).
Differential expression analysis identified 1248 and
3289 genes that changed expression in NPCs and neu-
rons, respectively (FDR < 0.05, Fig. 2a, Additional file 3:
Table S2). Note that CHD8 showed no significant ex-
pression change at the transcript level (p = 0.85 in
NPCs, p = 0.27 in neurons, Additional file 3: Table S2).
The fact that many more DEGs were detected in neu-
rons than NPCs indicates that persistent CHD8 hemi-
zygosity could have continuous and amplified effects in
neurodevelopment, i.e., genes with altered expression in
NPCs would directly affect the expression of additional
sets of genes in the differentiating neurons. Seven
DEGs, including SMARCA2, WNT7A, HMGA2, TESC,
TCF4, TGFβ3, and DDR2, which are involved in tran-
scription regulation, cell division, and WNT-β-catenin
signal pathways, or related to head size or brain volume
(see below), were selected for qRT-PCR analysis, and
their differential expression in CHD8+/− neurons was
confirmed (Fig. 2b). Of them, SMARCA2, HMGA2, and
TCF4 were potentially direct targets as they were
bound by CHD8 [25].
Previous studies have reported that CHD8 bound to
thousands of genomic regions (i.e., peaks), especially to




Fig. 2 Functional annotation of DEGs and their relationship to CHD8-binding. a Venn diagram of DEGs from CHD8+/− in iPSC-derived NPCs and
neurons. b qRT-PCR validation of seven DEGs, using β2-microglobulin (β2M) as a reference gene to calculate relative expression levels. The qPCR
was carried out on neurons derived from two control samples and the two CHD8+/− clones (the same samples used for the RNA-seq). Each was
normalized against another control sample. Samples were analyzed in triplicate. The graph shows the fold change for each sample relative to the
neutral control, error bars show the +/− standard deviation. The fold changes were highly significant: SMARCA2, p = 9.7E-7; WNT7A, p = 6.1E-9;
HMGA2, p = 4.4E-6; TESC, p = 0.003; TCF4, p = 4.4E-5; TGFB3, p = 5.5E-6; DDR2, p = 6.2E-8 (two-tailed Student’s t test). c Percentage of CHD8-binding
genes in all protein-coding, upregulated, and downregulated genes in NPCs, ranked by their expression values (FPKMs) in WT NPCs. Asterisks (“*”)
mark the groups of genes showing a significant difference in the proportions of genes with CHD8 binding by comparing DEGs with all protein-coding
genes (binomial test, two-tailed, p < 0.05). d Representative-enriched GO terms (top) and canonical pathways (bottom) among DEGs, as reported by
DAVID and IPA, respectively. The red color in each cell corresponds to the −log10(p value), corrected by Benjamini-Hotchberg method (color scale on
the left and only terms with p < 0.05 were shown)
Wang et al. Molecular Autism  (2015) 6:55 Page 6 of 18
the relationship between DNA binding and gene regu-
lation, we integrated CHD8 binding in control NPCs
[25] with our expression data. Based on the average
gene expression of the two WT NPC samples, we sepa-
rated genes into 10 bins of equal size (1284 genes per
bin). Consistent with the results from Sugathan et al.
[25], CHD8 binding was observed more frequently at
more highly expressed genes (Fig. 2c). To our surprise,
we found that the percentages of CHD8 binding genes
among the DEGs were significantly lower than the ex-
pectation from genome-wide binding (Fig. 2c). Never-
theless, this finding is consistent with previous reports
that only a small percentage of CHD8-bound genes dis-
played differential expression upon CHD8 knockdown
[25]. This result indicates that CHD8 directly regulates
a limited number of genes and that the majority of
gene-expression changes due to CHD8 knockout are
indirectly regulated targets.
GO analysis using DAVID revealed that upregulated
genes in CHD8+/− NPCs and neurons were enriched
with similar GO terms, including “extracellular region,”
“skeletal system development,” and “cell adhesion.” On
the contrary, for downregulated genes, except for the
GO term “neuron differentiation” that was enriched in
both NPCs and neurons, “neuron projection,” “synaptic
transmission,” and “transcription factor activity” were
only enriched in neurons (Fig 2d, see full list in Add-
itional file 4: Table S3). In addition, using IPA, we found
that DEGs were highly enriched in “axonal guidance sig-
naling,” “WNT-β-catenin signal,” and “PTEN signaling”
(Fig. 2d, full list in Additional file 5: Table S4). These re-
sults indicate that heterozygous CHD8 mutations may
disrupt multiple processes of neurodevelopment and
neural functions in ASD. It should be noted that, in
addition to nervous system development, the DEGs were
also enriched for cancers, gastrointestinal disease, and
cardiovascular system development, based on the IPA
analysis (Additional file 5: Table S4).
As genes downregulated in both CHD8+/− NPCs and
neurons were enriched for neuronal differentiation, we
wondered how heterozygous CHD8 KO might affect
gene regulation during the transition from NPCs to dif-
ferentiating neurons. To address this, we utilized a two-
factor linear model implemented in DESeq2 to search
for genes whose transitional expression from NPCs to
neurons were affected by CHD8 reduction (i.e., inter-
action between neuronal differentiation and CHD8 sta-
tus; see Methods). This analysis identified 1098 genes.
Among them, 360 also showed a significant differential
expression between NPCs and neurons in WT but not
in the comparison of CHD8+/− samples. Of these 360
genes, 207 genes were expressed at a higher level in WT
neurons (vs. WT NPCs). GO analysis revealed that these
genes were enriched in “neurological system process,”
especially in “transmission of nerve impulse” and “synap-
tic transmission” (Additional file 2: Figure S1A). The 153
genes with higher expression in WT NPCs (vs. WT neu-
rons) were enriched for “cell junction” and “cell adhesion”
(Additional file 2: Figure S1B). These results indicate that
normal synapse formation and function could be dis-
rupted during CHD8+/− neuron differentiation.
CHD8 direct targets vs. indirect targets
To better understand the regulatory roles of CHD8, we
further characterized the 407 DEGs in NPCs with CHD8
binding (i.e., direct targets) and used STRING to define
their function interactions, which include direct protein-
protein interactions and indirect functional associations.
Of the 407 genes, 140 were included in the resulted
STRING network, and interestingly, those genes could
be grouped into several function clusters: cell cycle,
cytoskeleton, cell adhesion, chromatin factor, ribonu-
cleoprotein complex, and GTPase genes (Fig. 3a), reveal-
ing major pathways that could be directly regulated by
CHD8 in NPCs. We did not perform the same analysis
for neuron DEGs because no CHD8-binding data was
available for human neurons.
As DEGs were statistically depleted of CHD8 binding,
we wondered how then those 841 NPC DEGs without
CHD8 binding (i.e., indirect targets) could be affected by
reduced CHD8 expression. To address this, we applied
IPA software to predict the upstream regulators of these
CHD8 indirect targets. The results showed that 12
CHD8 direct targets could serve as upstream regulators
of 95 of the 841 CHD8 indirect targets (Fig. 3b), includ-
ing ASD-risk genes MEF2 [64] and ARNT2 [65]. This
analysis also revealed that some DEGs could be regu-
lated by 35 DEGs that were, themselves, indirect targets.
Together, these 47 upstream regulators formed a com-
plex regulatory network (Fig. 3b), mediating key cellular
pathways (e.g., BMP and TGFβ) that eventually may lead
to expression changes for thousands of genes when
CHD8 expression is disrupted, an interesting finding to
be further investigated.
CHD8-regulated genes are overall longer than non-DEGs
We noticed that some extremely long genes were dys-
regulated in either NPCs or neurons, like LSAMP
(2187 kb), PCDH15 (1825 kb), RBFOX1 (1694 kb), and
NRXN3 (1622 kb). In addition, many high-confidence
ASD-candidate genes are exceptionally long [66]. At
the genome-wide level, we found that DEGs in both
NPCs and neurons were significantly longer than the
non-DEGs (Fig. 4). The length difference between
DEGs and non-DEGs was not detected in a separate
study in which we compared the iPSC-derived neurons
from schizophrenia patients with controls (manuscript
submitted; data available in the GEO: GSE46562); the
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AB
Fig. 3 Interaction network of CHD8 direct targets and a putative CHD8 regulatory network in NPCs. a Functional interaction network generated
by the STRING database for CHD8 direct targets, with nodes representing genes and edges representing interactions. Colors of the nodes indicate
expression changes. Disconnected genes were not shown. b A putative regulatory network connecting CHD8 to a set of upstream regulators,
which in turn could regulate the expression of many genes indirectly targeted by CHD8. The edges represent regulatory relationship predicted by
the IPA for upstream regulators that were bound (ellipse) or not bound (rectangle) by CHD8. Colors of the nodes indicate expression changes. Sizes
of the nodes show the –log10 (p value) from IPA. Arrows start from an upstream regulator to its targets. Note that only differentially expressed
upstream regulators were included in the network
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mean lengths were 77 kb for DEGs and 73 kb for non-
DEGs (p value = 0.51, Student’s t test). This indicates
that our observation is not simply a result of analyzing
expression data in the neural induction system we used.
This difference was detected for genes with CHD8-bind-
ing (Fig. 4a) or without CHD8-binding (Fig. 4b), suggest-
ing that other transcription regulators may cooperate with
CHD8 to regulate the expression of long genes.
DEGs are enriched for genes associated with human head
size/brain volume
Macrocephaly is overrepresented in ASD patients and a
defined feature of some syndromic forms of ASD, in-
cluding those carrying loss-of-function CHD8 mutations
[15, 16]. In addition, chd8 disruption in zebrafish re-
sulted in increased embryonic head size [15, 25]. We
thus used Toppgene to predict the potential phenotypes
that could result from the dysregulation of CHD8 tar-
gets. For downregulated genes in CHD8+/− neurons, “ab-
normality of skull size” was one of the most significant
human phenotypes (Fig. 5a), so were neurodevelopmen-
tal abnormality, intellectual disability, and abnormality
of brain morphology, all consistent with clinical pheno-
types seen in patients with CHD8-disruptive mutations
[15]. For the other gene groups, i.e., up- or downregu-
lated genes in CHD8+/− NPCs or upregulated genes in
CHD8+/− neurons, either no human phenotypes were
significantly enriched, or enriched phenotypes showed
no obvious relation to brain or head development
(Additional file 6: Table S5). It would be interesting to
further study how this difference detected for the DEGs of
CHD8+/− NPCs and neurons may be related to changing
CHD8 roles at different stages of brain development.
Next, we compared the lists of DEGs in CHD8+/−
NPCs and neurons with genes previously associated with
brain size or volumes of specific brain regions. Recent
GWASs revealed a small number of common variants
associated with the volumes of different human brain re-
gions or head sizes [67–69]. Remarkably, of the only 12
genes linked to the statistically significant GWAS vari-
ants, 7 were differentially expressed in CHD8+/− neu-
rons, which was significantly higher than expected (odds
ratio (OR) = 4.07, p = 0.016, Fisher’s exact test, one-
tailed; Table 1). HMGA2, a high-confident candidate
linked to adult intracranial volume [68] and infant head
circumference [69], was a CHD8 direct target (with
CHD8 binding to its promoter [25, 26]), and it was
upregulated in both CHD8+/− NPCs and neurons. Inter-
estingly, HMGA2 encodes a chromatin-associated regu-
lator important for stem cell renewal. How CHD8 and
HMGA2 interact and co-regulate gene-expression and
cell cycles warrants further study. Another DEG associ-
ated with caudate volume is FAT3, which codes for an
atypical cadherin previously shown to affect dendritic
pruning [70], a known defect in ASD. Interestingly, by
analyzing the spatiotemporal transcriptional data across
A B C
Fig. 4 Difference in gene length between DEGs and non-DEGs. Plotted here are length distributions of genes with CHD8 binding in NPCs (a),
without CHD8 binding in NPCs (b), and all genes in neurons (c). In NPCs, mean of gene lengths is 117 kb for DEG and 76 kb for non-DEG; in
neurons, mean of gene lengths is 98 kb for DEGs and 74 kb for non-DEGs, whereas gene lengths were defined as the distances from transcription
start site to termination site in Gencode v18. *p < 0.01, **p < 1e-5, ***p < 1e-9, t test, two-tailed
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developing brains available in the Brainspan project
[71], we found that the expression of CHD8 was signifi-
cantly and positively correlated with FAT3 during brain
development (Additional file 2: Figure S2), suggesting
that CHD8 is a positive regulator of FAT3, consistent
with the downregulation of FAT3 in CHD8+/−. MAPT,
another top candidate associated with infant head
circumference [69], was downregulated in CHD8+/−
neuron (nominal p value = 0.015).
DEGs are enriched with ASD and schizophrenia-risk genes
Functionally disruptive mutations in CHD8 have been
reported in multiple ASD patients as well as one spor-
adic schizophrenia patient [72]. Comparing our list of
A B
Fig. 5 Enrichment of DEGs for ASD/schizophrenia-risk genes and genes associated with specific human phenotypes. a Enriched human
phenotype from the Toppgene analysis for downregulated genes in neurons. p values were corrected by the Bonferroni method. b Enrichment
of DEGs for ASD- and schizophrenia-risk genes. ASD-risk genes were collected from the SFARI database [54], AutismKB core dataset [55], and four
other sets based on whole exome-sequencing and gene-expression network (Willsey_ASD [56], Liu_ASD [57], Iossifov_ASD [11] and DeRubei-
s_ASD [10]). The number of expressed genes in each set was in left parentheses. Schizophrenia-risk genes were obtained from either the SZGene
database [58] or a recent GWAS report [59]. The red color in each cell corresponds to the −log10 (p value) for enrichment (Fisher’s exact test, one-
tailed), as shown in the color scale on the right (shown only if p < 0.05). The first and the second number (in parenthesis) within each cell are the
number of overlapping genes and the odds ratio of overlap, respectively
Table 1 Expression changes of genes associated with brain volume or head size from GWAS





CHD8+/− NPC CHD8+/− neuron
log2(FC) q value log2(FC) q value
[68] Hippocampal volume rs7294919 TESC chr12:117476728-117537284 N 0.42 0.89 −2.78 0.0020
[68] Total brain volume rs10494373 DDR2 chr1:162601163-162750237 N 4.12 1.68E-31 5.70 2.82E-13
[68] Intracranial volume rs10784502 HMGA2 chr12:66217911-66360075 Y 1.00 3.57E-06 2.97 6.67E-08
[69] Infant head circumference rs1042725
[69] Infant head circumference rs7980687 SBNO1 chr12:123773656-123849390 Y −0.15 0.61 −0.45 0.023
[69] Infant head circumference rs11655470 MAPT chr17:43971748-44105700 N 0.61 0.40 −1.82 0.070
CRHR1 chr17:43699267-43913194 N 0.15 0.90 −0.13 0.86
[67] Intracranial volume rs17689882 CRHR1 chr17:43699267-43913194 N 0.15 0.90 −0.13 0.86
[67] Putamen volume rs945270 KTN1 chr14:56025790-56168244 Y −0.22 0.67 −0.09 0.80
[67] Putamen volume rs683250 DLG2 chr11:83166055-85338966 Y 0.66 0.69 −0.059 0.96
[67] Caudate volume rs1318862 FAT3 chr11:92085262-92629618 N −0.92 2.45E-05 −1.27 4.98E-06
[67] Putamen volume rs6087771 BCL2L1 chr20:30252255-30311792 Y 0.10 0.89 −0.67 0.029
[67] Hippocampal volume rs61921502 MSRB3 chr12:65672423-65882024 N 0.33 0.79 2.63 8.69E-24
[67] Putamen volume rs62097986 DCC chr18:49866542-51057784 Y 0.72 0.31 −0.18 0.1
Significant fold changes are set in italics
Wang et al. Molecular Autism  (2015) 6:55 Page 10 of 18
DEGs with ASD-risk gene sets from multiple sources
(see Methods), we found that upregulated genes in
CHD8+/− NPCs and downregulated genes in CHD8+/−
neurons were significantly enriched with ASD-risk genes
(Fig. 5b, Additional file 7: Table S6). In Table 2, we pro-
vided a list of high-confident ASD-risk genes that were
dysregulated in CHD8+/−. For the 163 ASD-risk genes
that were in our DEG lists, they were significantly
enriched for “transmission of nerve impulse,” “synaptic
transmission,” and “neuron differentiation,” further sup-
porting the importance of CHD8 in regulating synaptic
functions. In a comparison of our DEGs with the genes
associated with schizophrenia, we found that our DEGs
were enriched with schizophrenia-related genes from the
SCZgene database [58] but not enriched in the high-
confident gene list from a recent schizophrenia GWAS
[59] (Fig. 5b, Additional file 7: Table S6).
CHD8-regulated genes significantly overlap with the
targets of other autism-risk genes
Since ASD is caused by mutations in a diverse array of
genes involved in different cellular functions, we next set
out to address whether the dysregulated targets by dif-
ferent ASD-risk genes indeed converge on molecular
and cellular pathways. We thus searched for published
expression data reporting downstream targets of ASD
genes, especially transcriptional regulators. Recent stud-
ies reported that in human progenitor cells, reduced ex-
pression of transcription factor 4 (TCF4) and histone-
lysine N-methyltransferase 1 (EHMT1) converged at sev-
eral levels with respect to their downstream targets [51].
Also, the downstream targets of methyl-CpG-binding
domain 5 (MBD5) and special AT-rich binding protein
(SATB2) were converged in neural stem cells [52]. We
therefore decided to include these genes to our analysis
because their association with ASD has been described
previously [8, 73, 74], and their regulatory targets were
identified in NPCs using an experimental scheme similar
to ours, comparing expression changes by RNA-seq after
reducing expression of ASD-candidate genes that func-
tion as transcription regulators.
First, we compared the DEGs from these studies with
ours. Note that in CHD8+/− NPCs, TCF4 was upregu-
lated (3.4-fold increase, q value = 1.58e-19), but no ex-
pression changes were observed for the other three. We
found that our list of DEGs in NPCs showed significant
overlap with the DEGs found in the TCF4, EHMT1, and
MBD5 knockdown studies (Fig. 6a, Additional file 8:
Table S7). To search for functional commonality, we an-
alyzed the 439 genes that were affected by at least two of
the five ASD genes. Again, we used STRING to define
function interactions among these 439 genes. The results
indicated that the common genes were mainly distrib-
uted in two highly interconnected clusters (Fig. 6b). One
was significantly enriched for genes involved in forming
extracellular matrix (p = 5.83e-12, Additional file 8: Table
S7), including multiple collagen genes. The other was
highly enriched with cell cycle-related genes (p = 6.78e-9,
Additional file 8: Table S7), though the enrichment was
mainly derived from the common genes between EHMT1
and MBD5 knockdown. Genes critical for neurogenesis,
like PLP1 and GFAP, were also significantly enriched (p =
Table 2 Selected differentially expressed genes associated with ASD risk
Gene Coordinate ASD score CHD8-
binding
in NPCs
CHD8+/− NPC CHD8+/− neuron
SFARI AutismKB Willsey log2(FC) q value log2(FC) q value
ANK2 chr4:113739265-114304896 High confidence 9 hcASD N −1.87 1.36E-45 −1.96 6.32E-08
SETD5 chr3:9439299-9520924 High confidence 10 Y 0.25 0.67 0.87 0.00053
SUV420H1 chr11:67922330-67981295 High confidence 16 hcASD Y −0.084 0.89 −0.86 0.0020
SCN2A chr2:166095912-166248818 High confidence 20 hcASD N −0.64 0.86 −3.31 5.67E-05
DEAF1 chr11:644233-706715 Strong candidate 2 N −0.16 0.79 −0.68 0.0010
MYT1L chr2:1792885-2335032 Strong candidate 2 N 0.67 0.72 −1.76 0.0077
BCL11A chr2:60678302-60780702 Strong candidate 9 N 1.91 0.029 0.25 0.61
CNTN4 chr3:2140497-3099645 Strong candidate 9 N 6.02 0.53 5.15 1.60E-14
CACNA2D3 chr3:54156574-55108584 Strong candidate 10 pASD Y 2.64 0.0036 −2.95 0.00076
CACNA1H chr16:1203241-1271771 Strong candidate 10 Y 0.75 0.045 −0.19 0.58
NRXN1 chr2:50145643-51259674 Strong candidate 28 pASD Y −0.81 0.77 −1.71 2.13E-05
MET chr7:116312444-116438440 Strong candidate 33 N 0.69 0.82 −3.56 3.45E-05
GABRB3 chr15:26788693-27184686 Strong candidate 34 N −0.43 0.66 −1.70 0.00030
RELN chr7:103112231-103629963 Strong candidate 43 pASD N 1.82 0.16 −2.92 1.46E-06
Significant fold changes are set in italics
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1.14e-8, Additional file 8: Table S7), but they showed
sparse connection, perhaps because of incomplete infor-
mation in the interaction database.
Next, we carried out the same analysis for DEGs in
neurons, including data from our current study and a
previous study in which neurexin 1 (NRXN1) expression
was reduced [75]. NXRN1 was downregulated in CHD8
knockout neurons (3.2-fold reduction, q value = 2.84e-4).
Again, we found a significant overlap of the DEGs from
CHD8 knockout neurons with those in NRXN1 knock-
down neurons (Fig. 6a). The overlapping genes were,
again, enriched for “extracellular matrix.”
The transcriptional targets of zinc finger protein
804A (ZNF804A), a top schizophrenia candidate, were
recently reported by our group from RNA-seq analysis
in which the gene was knocked down in neurons
derived from iPSCs [49]. While the overlap of DEGs
from differentiating neurons with CHD8 knockout and
ZNF804A knockdown was not significant (Fig. 6a), the
overlap of DEGs from ZNF804A knockdown and
NRXN1 knockdown was highly significant (OR = 2.63,
p = 0.023, Fisher’s exact test, one-tailed). These results
suggest that both common and unique transcription tar-
gets exist for neuropsychiatric disorder candidate genes
that code for gene-expression regulators. It should also be
noted that previous studies have also reported a conver-
gence of genes affected by SATB2 knockdown and MBD5
knockdown [52].
In summary, our comparison of genes that show ex-
pression changes upon knockout or knockdown of key
genes implicated in major neuropsychiatric disorders
found that many downstream target genes were com-
monly affected by several transcription factors and epi-
genetic modifiers, and the common genes were often
enriched for those that code for “cell cycle,” “extracellu-
lar matrix,” and “cell proliferation.”
Comparison with previous results from CHD8 knockdown
studies
We compared our lists of DEGs with other four lists of
DEGs that were obtained by knocking down CHD8 ex-
pression in neural cells [25–27]. Except for the two lists
from two independent shRNA knockdowns in the same
study, DEG lists from different analyses showed modest
overlap; at most, 30–40 % of DEGs in one list were de-
tected in other studies (Additional file 2: Figure S3).
Whereas the overlap from different studies was mod-
est, we considered the possibility that the DEGs from
different studies might converge on common functional
pathways. We thus performed GO enrichment analysis
for each of the five lists of DEGs and then focused on
the 327 GO terms that were enriched in at least three
DEG lists (Additional file 9: Table S8). Among them,
only four terms were present in all five DEG sets (re-
ferred to as “5 L” terms) and 31 terms (“4 L” terms) were
shared by four studies. When the functions of these 327
A B
Fig. 6 Overlap between DEGs from CHD8+/− and previous knockdown studies of other ASD-risk genes. a Enrichment test for the overlaps between
DEGs from CHD8+/− NPCs and knockdowns of TCF4, EHMT1, MBD5, or SATB2, and between DEGs from CHD8+/− neurons and knockdowns of ZNF804A
or NRXN1. Bars represent p value (Fisher’s exact test, one-tailed), red dots represent odds ratio of overlap. b Network analysis of genes that
were differentially expressed in NPCs in either CHD8+/− or knockdown of at least two of the five genes (CHD8, TCF4, EHMT1, MBD5, and SATB2).
The network was generated by STRING, with nodes representing genes and edges representing interactions. Size of the nodes is proportional
to their connectivity. Colors of the nodes label the sources of DEGs. Two natural clusters are demarcated with ellipses. Disconnected genes
were not shown
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GO terms were grouped by the software GlueGO [61],
however, 13 major functional clusters emerged (Fig. 7).
The largest cluster, harboring 72 individual GO terms,
was involved in cell communication, to which all of the
5 L terms belonged. This suggests that one common ef-
fect of reduced CHD8 expression across all studies is cell
communication and signal transduction. Some of the
DEGs from our CHD8+/− analysis are regulators of
major signaling pathways, for example, NFATC1 and
BMP2/4, and WNT7A (Fig. 3b). This finding was further
supported by the observation that 62 % of the 4 L terms
(n = 22) were located within similar function clusters (in-
dicated by high density of grey lines between them),
such as cellular protein metabolic process, RNA meta-
bolic process, and cellular response to stimulus. The sec-
ond largest cluster was “neuron development,” including
66 specific GO terms related to neuron differentiation,
axon guidance, and synapse organization, etc. This indi-
cates that CHD8 disruption has a profound effect on
multiple aspects of neurodevelopment. Note that the
two DEG lists from shRNA knockdown in the study by
Cotney et al. were not enriched for this large functional
cluster. However, cell cycle pathways were particularly
enriched in those two lists, suggesting that the samples
in that study might be in a more proliferative and less
“neural-like” state. This integrated analysis also identified
a number of GO terms clustered into programmed cell
death and cytoskeleton organization, consistent with the
previously reported interactions between CHD8 and
p53-mediated apoptosis [23] and the Wnt-β-catenin sig-
naling pathway [19]. In addition to well-known func-
tional clusters involving CHD8, including cell adhesion
and extracellular matrix organization, our bioinformatics
analysis suggests that cell migration and skeletal devel-
opment could also be a common theme affected by re-
duced CHD8 expression.
Finally, we compared the five lists of DEGs to the results
in a recent analysis of telencephalic organoids generated
from idiopathic autism patient-specific iPSCs [76]. Of the
differentially expressed genes in two developmental stages
Fig. 7 Enriched GO terms shared among five lists of DEGs from four studies. DEGs were from CHD8+/− NPC (current data), NPC knockdown
(NPC_KD) [25], NSC knockdown by two independent shRNAs (NSC_KD_shC, NSC_KD_shG) [26], or SK-N-SH knockdown (SK-N-SH_KD) [27].
Nodes represent common GO terms (names not displayed) and grey edges between them depict the degrees of gene overlap between terms.
GO Terms enriched in 3, 4, and 5 DEG lists are colored blue, orange, and red, respectively. Individual GO terms with a similar gene composition
were clustered into functional groups by ClueGO and drawn together as circles, with the functions labeled in red font. Square boxes represent each
of the five DEG lists and colored edges connect enriched GO terms in individual studies. This visualization was created using ClueGO plugin in
the Cytoscape
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(TD11 and TD31) of the organoids between ASD and
control samples [76], 516 and 1060 were expressed in our
samples. When the DEGs in CHD8+/− or CHD8 knock-
down studies were compared to the organoid DEGs, our
CHD8+/− showed the largest overlap with the organoid
data (Fig. 8, Additional file 2: Figure S3). GO analysis indi-
cated that the dysregulated genes common in CHD8+/−
samples and ASD organoids were significantly enriched
for genes involved in skeleton system development, cell
adhesion, and neuron differentiation (Fig. 8), indicating
that these could be functional pathways commonly dis-
rupted in ASD. Interestingly, the brain volume-associated
gene FAT3 was upregulated in TD31, further suggesting
the potential importance of FAT3 in ASD.
Discussion
To better understand the effect of genetic disruption of
CHD8 in ASD subjects, we have applied CRISPR/Cas9
technology to knockout one copy of CHD8 in a control
iPSC line and studied its effect on gene expression dur-
ing early neurodevelopment. In comparison to previous
studies [25–27] that used a gene knockdown approach
to reduce CHD8 expression, our approach generated
heterozygous disruptions that better mimic the germline
mutations in ASD patients and allows for the study of
long-term effects of CHD8 disruption in neurogenesis in
vitro. In addition, creating CHD8+/− iPSCs provides a
truly renewable resource for investigators, as opposed to
NPCs, which have a finite replicative capacity. Further-
more, iPSCs can differentiate into any cell type, includ-
ing cerebral organoids [77]; NPCs are restricted in their
differentiation potential.
Perhaps one of the most important findings emerging
from our transcriptomic analysis is that several genes
known to be related to head size or brain volume, either
from the analysis of human phenotype ontology [46] or
identified through GWAS [67–69], displayed significant
changes in their expression in CHD8+/− neurons. Studies
examining CHD8 function in zebrafish during embry-
onic development revealed that the macrocephaly
phenotype observed in ASD probands with CHD8 muta-
tions is likely caused by disturbed neuronal proliferation
at early developmental stages [15, 25]. By uncovering
genes like HMGA2 and FAT3, which have been associ-
ated with head size, our finding thus provides new mo-





Fig. 8 Comparison of DEGs from CHD8+/− and DEGs from brain ASD organoids [76]. Venn diagrams of DEGs from CHD8+/− NPCs (a) or neurons
(b) and DEGs from brain organoids. The number in each section represents genes that are also expressed in our samples. Top-enriched GO terms
for overlapped genes between DEGs from CHD8+/− NPCs (c) or neurons (d) and DEGs from brain organoids referred to as TD11 and TD31
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to abnormal neuronal proliferation and macrocephaly.
This association between macrocephaly and ASD is not
the first to be reported in genetically defined subgroups.
Mutations in PTEN are also associated with severe
macrocephaly and ASD [78]. Although PTEN itself was
not differentially expressed in our CHD8+/− samples,
FOXO1 and FOXO3, two critical transcription factors in
PTEN signaling, were. Interestingly, IPA analysis of the
differentially expressed genes reported an enrichment of
genes in PTEN signaling, suggesting that there may be a
link between the PTEN and CHD8 pathways, and the
molecular link underlies the observed macrocephaly and
ASD. In this regard, we should mention that PTEN was
differentially expressed upon CHD8 knockdown in NPCs
in a previous study [25]. We should also point out there
were additional genes in our DEG lists that have been
previously suggested to be associated with hippocampal
volumes, such as BDNF, DISC1, and NRG1.
Dysregulated genes in CHD8+/− cells exhibited signifi-
cant overlap with previously defined ASD-risk genes,
including some high confident candidates like ANK2,
SCN2A, and SUV420H1 [54] that also showed significant
differential expression (Table 2). We further demon-
strated, interestingly, that CHD8-regulated genes signifi-
cantly overlapped with the downstream targets of other
ASD-risk genes like TCF4 and NRXN1, providing tran-
scriptomic evidence that ASD-risk genes have overlap-
ping function and converge on downstream regulatory
pathways. This is extremely important in a genetically
heterogeneous condition, such as ASD, in which any in-
dividual candidate gene carrying deleterious mutation
may only contribute to 1~2 % ASD cases [79]. TCF4 is
associated with Pitt-Hopkins syndrome (MIM: 610954),
which is defined by severe psychomotor delay, epilepsy,
daily bouts of diurnal hyperventilation, mild postnatal
growth retardation, postnatal microcephaly, and distinct-
ive facial features [80]. It is also a top schizophrenia can-
didate gene. In NPCs and NSCs, CHD8 binds to the
TCF4 gene body in a region that is also enriched with
H3K27ac [25, 26], a histone modification associated with
active enhancers. TCF4 is significantly upregulated in
both CHD8+/− NPCs and neurons. Moreover, TCF4-
regulated genes significantly overlapped with CHD8-reg-
ulated genes. Taken together, these results suggest a dir-
ect connection between TCF4 and CHD8 regulatory
networks. The common genes in the two networks, es-
pecially those regulated oppositely by CHD8 and TCF4,
such as HMGA2, which was upregulated in CHD8+/−
(Table 1) and downregulated in TCF4 knockdown [81],
are strong candidates for regulating the development of
brain size.
It was intriguing to find that DEG lists from different
CHD8+/− or knockdown studies had only limited over-
laps. A recent study of knockout vs. knockdown in
zebrafish egfl7 proposed that compensatory networks
would be activated to buffer against deleterious muta-
tions from knockout, which was absent in knockdown
[82], providing a potential explanation for the lack of
good overlap among CHD8 KO and KD findings. How-
ever, we found that at the function and pathway levels,
genes involved in similar functions were affected by re-
duced CHD8 expression in different contexts. It is con-
ceivable that a limited number of upstream regulators
are directly regulated by CHD8, and the subsequent re-
sponse of the downstream targets is mostly dependent
on genetic background, cell culture conditions, and
other experimental factors. In this regard, we should
mention that five (GDPD4, VPS13B, KMT2C, SETBP1,
and CLTCL1) of the ~1000 ASD-risk genes were pre-
dicted to be functionally disrupted by premature stop or
frameshift variants located to the coding exons of the
subject used to prepare our WT iPSC line (Additional
file 10: Table S9 and S10). However, none of these five
genes exhibited differential expression in the WT neu-
rons when compared to samples from other control
iPSC lines derived from six unrelated subjects (data
not shown). As neuronal differentiation is a complex
process, affected by both environmental cues and in-
trinsic cellular signaling, our analysis suggests that it is
important to study the effects of the same genes under
different experimental conditions. Nevertheless, com-
parison of our results with the transcriptomic data in
ASD-derived organoids indicates that reduction of
CHD8 expression in our CHD8+/− samples is probably
more consistent with the gene regulation in ASD-
developing brains, although it should be noted that
the ASD-derived organoids were from patients with
unknown genetic mutations.
As most of the functionally disruptive mutations un-
covered in the CHD8-coding regions in the ASD pro-
bands introduce premature stop or frameshift mutation
[15, 16], we used CRISPR/Cas9 technology to make
small deletions in the first coding exon of CHD8 in this
study. While the 2- or 10-bp deletion is predicted to
cause frameshift, and no functional protein is expected
from the mutants, RNA transcripts from the knockout
CHD8 copy were observed in our RNA-seq data, indicat-
ing nonsense mediated mRNA decay is incomplete if it
occurs to the mutated CHD8 transcripts (Fig. 1). CHD8
encodes a multi-domain protein, and deleterious muta-
tions in CHD8 have been found in almost every import-
ant functional domain [15, 16]. While our data indicate
that CHD8 regulates multiple pathways related to neural
development, the different mutations in ASD individuals
may impair distinct and specific aspects of CHD8 func-
tions. In the future, it will be valuable to carry out gene-
expression profiling using ASD-specific iPSCs to see
how our current findings can be recapitulated in
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additional iPSC-derived NPCs and neurons. As genetic
background likely plays an important role in modulating
CHD8 function during brain development, it is important
to both perform our current knockout analysis in add-
itional control iPSC lines and to derive patient-specific
lines from multiple ASD individuals with CHD8 muta-
tions. In addition, it will be extremely valuable to apply
CRISPR technology to correct the CHD8 mutations and
perform transcriptomic analysis and other molecular as-
says once the patient-specific lines are established.
Conclusions
CHD8 regulates multiple genes involved in cell commu-
nication, extracellular matrix and neurogenesis that are
critical for brain development. In addition, CHD8 hemi-
zygosity causes expression changes in several genes that
are associated with brain volume or head size, suggesting
a molecular link between CHD8 mutation and macro-
cephaly. By cross-analysis of several studies in which the
expression of several ASD-candidate genes was reduced,
we provide evidence that the transcription targets of
ASD genes converge on a set of genes and pathways.
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